Millennium Management’s Fate Therapeutics FATE Stock Holding History

Millennium Management’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-50,000	Closed	-$175K	–	6091
2024 Q3	$175K	Buy	+50,000	New	+$195K	﹤0.01%	5480
2022 Q1	–	Sell	-10,000	Closed	-$585K	–	7066
2021 Q4	$585K	Buy	+10,000	New	+$567K	﹤0.01%	4910
2021 Q2	–	Sell	-10,000	Closed	-$825K	–	6672
2021 Q1	$825K	Buy	+10,000	New	+$958K	﹤0.01%	4393

Other funds holding FATE

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Millennium Management's FATE Position: Q2 2026 in Review

Millennium Management opened a new position in Fate Therapeutics (FATE) in Q2 2026: 2,433,978 shares worth $6.57M. The stake represents ﹤0.01% of the portfolio and ranks #2732 among its holdings. This is a return to the name: Millennium Management previously reported a position in FATE as recently as Q4 2025.

Millennium Management first reported a position in FATE in Q4 2013 and has held it in 40 quarters since. The position peaked at $52.1M in Q3 2019. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

Millennium Management held 2,433,978 shares of Fate Therapeutics worth $6.57M as of Q2 2026.
Fate Therapeutics was a new Millennium Management position in Q2 2026.
Fate Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q2 2026, its #2732 holding.
Millennium Management first reported a position in Fate Therapeutics in Q4 2013 and has held it in 40 quarters since.
Millennium Management's Fate Therapeutics position peaked at $52.1M in Q3 2019.
156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.